Overview

Study to Establish the Diagnostic Performance of 18F Fluciclovine PET in Detecting Recurrent Brain Metastases

Status:
Recruiting
Trial end date:
2022-03-01
Target enrollment:
Participant gender:
Summary
An open-label, single dose, single arm, prospective, multicenter Phase 3 study to establish the diagnostic performance of 18F fluciclovine positron emission tomography (PET) in detecting recurrent brain metastases after radiation therapy
Phase:
Phase 3
Details
Lead Sponsor:
Blue Earth Diagnostics
Collaborator:
Precision For Medicine